COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
Executive Summary
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.
You may also be interested in...
Getinge Sees Q1 Acute Care Orders Jump 96%, Plans Major Investment In ECMO
The Swedish company has seen a spike in orders of acute care products to treat COVID-19 patients and plans a multi-million investment to expand long-term ECMO production.
AdvaMed CEO Says Some Top Agenda Items For the Year Are ‘Taking A Back Seat’ To Address COVID-19
AdvaMed has had to adjust to the new COVID-19 reality like everyone else. In an exclusive interview with Medtech Insight, the head of the industry group says they are putting some key issues such as user-fee negotiations, anti-kickback legislation and breakthrough technologies reform on the back burner to prioritize dealing with the current crisis.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?